Study Comparing the Effectiveness and Tolerance of Two Emollient Creams for Treating Atopic Dermatitis in Adults

What this Trial Is About

Atopic dermatitis AD is a long-lasting inflammatory skin condition marked by redness, scaly and oozing patches, and intense itching, which negatively affects quality of life and sleep. The disease has two phases flare-up and remission. AD symptoms relate to immune system problems, skin barrier defects, skin microbiome imbalance, and overall inflammation. This research is designed to assess and compare how well two face and body creamsone new emollient and one placebowork and how well they are tolerated in adults with atopic dermatitis over five weeks. It is an interventional, single-center, double-blind, randomized, and comparative study. Participants will be randomly assigned to use either the new emollient cream or a placebo cream on their face and body as a substitute for their usual skin moisturizer. The study duration for treatment is five weeks. The study groups include the experimental arm using the anti-itching and repairing emollient and the placebo arm using a non-active cream. Both treatments are applied topically during the study period. During the trial, participants will be assessed at several time points including the start Day 0, between Day 5 and Day 10, and again 28 days after Day 5 to Day 10. Researchers will measure the severity of eczema using SCORAD and EASI scores, assess skin water loss using a Vapometer, analyze skin microbiota samples, and collect participant-reported outcomes through quality of life and sleep quality questionnaires. Safety will be monitored throughout the study. Total participation spans these assessments and treatment applications over the study period.

Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis